Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie has submitted an application to the European Medicines Agency (EMA) for risankizumab (SKYRIZI) as a treatment for moderate to severe active Crohn's disease in patients aged 16 and older. This application is based on results from three pivotal Phase 3 studies: ADVANCE, MOTIVATE, and FORTIFY, which demonstrated significant improvements in clinical remission and endoscopic response. No new safety risks were identified compared to the existing safety profile. Approval is still pending, and risankizumab's use for Crohn's disease has not yet been established by regulatory authorities.
AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on December 2, 2021, at 11:10 a.m. CT. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will present. A live audio webcast will be available on AbbVie’s Investor Relations website, with an archived edition accessible later that day. AbbVie aims to discover innovative medicines to address serious health issues across various therapeutic areas, including immunology and oncology.
AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:30 a.m. CT. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will present during the event. The presentation can be accessed via a live audio webcast on AbbVie's Investor Relations website, with an archived version available later that day. AbbVie is dedicated to discovering innovative treatments across various therapeutic areas, including immunology, oncology, and neuroscience.
On November 19, 2021, AbbVie announced that its Allergan Aesthetics division will present six abstracts at the virtual American Society for Dermatologic Surgery meeting from November 19-21. The presentations will highlight innovative findings on aesthetic treatments, particularly featuring BOTOX® Cosmetic. Two abstracts received recognition as 'Best of Cosmetic Oral Abstracts.' One of the sessions, led by Dr. Arisa Ortiz, will showcase the SkinMedica® TNS® Advanced+ Serum's efficacy in enhancing skin appearance. This meeting reinforces Allergan's commitment to advancing aesthetic medicine.
On November 18, 2021, AbbVie published a literature review in Advances in Therapy, outlining the economic benefits of achieving clinical remission in rheumatoid arthritis (RA). The review indicates that remission is linked to substantial cost savings: 19%-52% in direct medical costs and 37%-75% in indirect costs. Patients with sustained remission experience fewer disease flares and require less medical intervention. The findings emphasize the importance of treatment strategies aimed at reaching remission, as recommended by clinical guidelines. The review analyzed 16 studies from various countries, emphasizing the crucial role of remission in enhancing patient quality of life.
AbbVie announced that the European Commission has approved SKYRIZI® (risankizumab) for treating adults with active psoriatic arthritis who have not responded adequately to other treatments. This approval, based on Phase 3 clinical trials KEEPsAKE-1 and KEEPsAKE-2, marks the second indication for SKYRIZI in the EU. The studies reported significant improvements in patient outcomes, with 57.3% and 51.3% of participants achieving the primary efficacy endpoint at week 24, compared to placebo. The safety profile aligns with previous data, showing no new risks.
AbbVie has extended its collaboration with the University of Chicago through 2025 to bolster preclinical oncology research. This partnership has yielded insights into biomarkers and novel drug delivery strategies enhancing anti-tumor immune responses. The extension aims to further accelerate medical research in oncology, with AbbVie gaining exclusive licensing rights to certain discoveries. AbbVie emphasizes the collaboration's potential impact on public health and aims to leverage findings for developing innovative cancer therapies.
AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on November 17, 2021, at 8:30 a.m. Central time. Key executives including Dr. Michael Severino, Robert A. Michael, and Jeffrey R. Stewart will present at the event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie's mission focuses on delivering innovative medicines in various therapeutic areas, including immunology, oncology, and more.
AbbVie (NYSE: ABBV) reported promising results from post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials, demonstrating that upadacitinib (RINVOQ®) provided greater clinical responses for active psoriatic arthritis (PsA) patients with axial involvement compared to both placebo and HUMIRA® at 24 weeks. Specifically, 69.8% of patients on upadacitinib achieved clinically important improvement. Safety profiles were consistent with previous studies, with no new risks identified. Upadacitinib is currently under FDA review for PsA treatment.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
